TM editors’ note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.
We are now in earnings season for Canadian licensed marijuana producers and so far the numbers have been quite impressive.
This has been one of the hottest sectors to own over the last year and we remain bullish on account of due the improving fundamentals, emerging international market opportunities (Australia, Germany, Colombia, Denmark, etc.), the funded growth initiatives focused on increasing production capacity, and the long-term opportunity presented by this sector.
Over the last two weeks, three leading Canadian marijuana producer have released financial and operating results and we have highlighted below some of most important numbers below. We believe that these represent some of the best long-term opportunities and investors should be monitoring these companies.
MedReleaf: Quarterly Revenue Receives Boost from Cannabis Oil
Yesterday, MedReleaf Corp. (LEAF.TO) (MEDFF) traded higher after releasing financial and operating results for the third quarter which ended on December 31st. During the quarter, MedReleaf recorded a $5 million net loss on $11.4 million in revenue. When compared to the prior quarter, sales grew by 16% while the net loss increased due to the stock based compensation expense as well as greater operating and advertising expenses.
The marijuana producer benefited from a trend toward smokeless products and the higher revenue was primarily due to cannabis oil products. During the quarter, sales of dried cannabis were $8.6 million (a decrease of 13% from the prior year period) while extract sales were $2.3 million (an increase of $2.1 million from the prior year period)
Cannabis oil accounted for 21% of MedReleaf’s total revenue during the quarter and this number should increase with the launch of topical creams, softgel capsules, future product development initiatives, and growing industry demand.
Leave A Comment